Lipoid's "New" Depigmentation Active Is the Same Platform, Repackaged for a Regulatory Moment

Lipoid Kosmetik's newest pigmentation active arrives with a familiar shape. Depigmentation Factor pairs bearberry leaf extract with the company's liposomal delivery system, according to the Swiss ingredient maker, and carries certification from COSMOS and NATRUE. That combination, a plant-derived tyrosinase inhibitor wrapped in phospholipid carriers, is the same basic architecture behind at least three other actives the company has shipped in recent years: Lipoid Liposome C Eco (ascorbyl glucoside), BakuLipid (bakuchiol), and the older Citrolumine 8 (citroflavonoids), according to product pages from SpecialChem and Industries Cosmétiques.

The repetition is not necessarily a weakness. Liposomal encapsulation is a genuine point of differentiation in an active-ingredient market where brightening chemistry itself is well understood but delivery and skin tolerance are not. What the pattern does suggest is that Lipoid is running one platform, controlled release of known lightening compounds, through multiple botanical front ends, and selling each iteration as a distinct launch. Depigmentation Factor's news cycle is less a chemistry breakthrough than a repositioning of a delivery system the company has already proven, timed to a moment when regulators are closing doors on the ingredients that built the category.

That timing is the real story. The EU's Scientific Committee on Consumer Safety flagged kojic acid in a 2021 preliminary opinion as potentially unsafe even at low concentrations, citing possible endocrine-disrupting effects, and recommended combined-use limits as low as 0.04 percent. Regulation (EU) 2024/996 names kojic acid alongside genistein and daidzein as skin-bleaching agents now under formal review. Arbutin, long marketed as the gentler cousin of hydroquinone, has its own exposure problem: the SCCS's final 2023 opinion capped alpha-arbutin at 2 percent in face creams specifically because it hydrolyzes into hydroquinone once it reaches skin. Hydroquinone itself has been banned outright in EU cosmetics since 2000.

In the United States, the FDA went further in June, issuing a consumer warning that there are no FDA-approved over-the-counter skin-lightening products at all, warning of kidney damage, neurological effects, and ochronosis, a permanent darkening of skin, from mercury and hydroquinone contamination. Enforcement has followed the warning into retail shelves: the Philippine FDA has recalled hydroquinone-contaminated products this year, and Maharashtra's state drug regulator declared nine mercury-tainted lightening creams substandard in July. Analysts at Mordor Intelligence point to exactly this regulatory squeeze, rather than consumer taste alone, as the force pushing ingredient suppliers toward alternative actives.

Lipoid's pitch rests on a claim the trade press has repeated without much interrogation: that there is sustained demand for lightening products which work visibly but use natural, skin-comfortable ingredients. That demand is real, but the market data behind it is inconsistent enough to be worth naming rather than citing as settled fact, with estimates for the global skin-lightening category ranging from roughly 18 billion dollars upward depending on which research firm is counting and what it includes. More telling is what Global Market Insights has found inside that number: synthetic actives, hydroquinone and kojic-acid derivatives among them, still dominate the market because formulators and dermatologists consider them more proven. Natural reformulation is a response to regulatory risk as much as it is a response to consumer pull.

The arbutin question matters here specifically, because bearberry leaf extract is an arbutin source. The same hydrolysis mechanism that led the SCCS to cap arbutin concentrations in standard formulations applies to bearberry-derived actives generically, which raises a question Lipoid's launch materials do not address: whether liposomal encapsulation changes the release profile enough to avoid the exposure levels regulators are worried about, or whether it simply delivers the same arbutin into skin more efficiently. Lipoid's literature emphasizes visible fading and comfort. It does not, in the material reviewed, address dose or hydrolysis behavior at the concentrations it recommends.

There is also a category the ingredient trade press rarely touches: who actually buys these products, and why regulators are paying attention now. The FDA's June warning noted that mercury- and hydroquinone-tainted lightening creams are marketed disproportionately to people with darker skin tones, a colorism dimension that sits upstream of any single ingredient debate. Lipoid's positioning, built on safety and naturalness, speaks to the liability side of that problem without engaging the demand side: why the pressure to lighten skin persists regardless of which compound delivers it. A formulation can be COSMOS-certified and still sell into a market shaped by that pressure.

Where the category goes next looks more likely to resemble tranexamic acid's trajectory than bearberry's. A 2026 clinical review found TXA effective for melasma, if slower-acting than hydroquinone, and it has moved from dermatology offices into mainstream retail serums, usually paired with niacinamide, without carrying arbutin's hydrolysis baggage or kojic acid's endocrine flag. Lipoid's liposomal platform could in principle carry TXA as easily as bearberry. For now, the company has chosen to launch its fifth variation on a familiar theme into a market where the ingredients regulators are least worried about are the ones increasingly showing up on ordinary drugstore shelves.